Credit Suisse Group Analysts Give Puma Biotechnology (PBYI) a $142.00 Price Target

Credit Suisse Group set a $142.00 target price on Puma Biotechnology (NASDAQ:PBYI) in a research report released on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on PBYI. Zacks Investment Research cut Puma Biotechnology from a hold rating to a sell rating in a research report on Monday. Citigroup reissued a buy rating and set a $156.00 price objective (up previously from $114.00) on shares of Puma Biotechnology in a research report on Thursday, October 5th. JPMorgan Chase & Co. reissued a buy rating and set a $131.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Stifel Nicolaus lifted their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the company a buy rating in a research report on Monday, October 2nd. Finally, ValuEngine cut Puma Biotechnology from a hold rating to a sell rating in a research report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Puma Biotechnology currently has an average rating of Buy and a consensus price target of $130.67.

Shares of Puma Biotechnology (NASDAQ PBYI) opened at $88.25 on Monday. The stock has a market capitalization of $3,310.00, a price-to-earnings ratio of -10.78 and a beta of 0.72. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The firm had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the business posted ($1.11) EPS. equities research analysts anticipate that Puma Biotechnology will post -8.17 earnings per share for the current fiscal year.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 21.10% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of Puma Biotechnology in the second quarter worth about $146,000. Sei Investments Co. bought a new position in shares of Puma Biotechnology in the third quarter worth about $256,000. Kazazian Asset Management LLC bought a new position in shares of Puma Biotechnology in the second quarter worth about $209,000. Ameritas Investment Partners Inc. increased its stake in shares of Puma Biotechnology by 5.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 140 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Puma Biotechnology in the second quarter worth about $222,000. Institutional investors and hedge funds own 96.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://weekherald.com/2018/01/19/credit-suisse-group-analysts-give-puma-biotechnology-pbyi-a-142-00-price-target.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply